文献速递腹部MR

肝脏肉瘤样癌:采用肝脏影像报告和数据系统的磁共振成像评估

Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system.
PubMed 文献 · Eur Radiol · 2019-03-11

本研究回顾184例病理确诊的肝脏肉瘤样癌(46例)、肝细胞癌(92例)和肝内胆管癌(46例),按LI-RADS v2017评估MRI分类。在33例有慢性肝病风险的肉瘤样癌中,72.7%(24/33)归为LR-M;归为LR-4/5/5V的肉瘤样癌中位直径1.9 cm,显著小于LR-M/MV的4.3 cm(p=0.012)。结论为大多数肉瘤样癌可归为LR-M,但小病灶可能与肝细胞癌难以区分。

要点

  • 有慢性肝病风险的肉瘤样癌中72.7%(24/33)按LI-RADS v2017归为LR-M。
  • 归为LR-4/5/5V的肉瘤样癌中位直径1.9 cm(范围1.0-4.2 cm),小于LR-M/MV的4.3 cm(范围1.3-20.6 cm),p=0.012。
  • 肉瘤样癌的MRI表现多与肝内胆管癌相似;靶样表现和包膜回缩在肝内胆管癌中比肉瘤样癌更常见(p≤0.009)。

核心结论

  • 大多数肉瘤样癌在MRI上可按LI-RADS v2017归为LR-M,但小病灶可能与肝细胞癌无法区分。

研究设计与样本

  • 回顾性研究纳入2006年1月至2017年12月病理确诊的184例患者,其中肉瘤样癌46例、肝细胞癌92例、肝内胆管癌46例;两名阅片者按LI-RADS v2017独立评估MRI。

关键影像表现/征象

  • 肉瘤样癌的MRI特征整体更接近肝内胆管癌而非肝细胞癌。
  • 靶样表现和包膜回缩在肝内胆管癌中比在肉瘤样癌中更常见(p≤0.009)。

诊断标准与关键数值

  • 肉瘤样癌按LI-RADS v2017归为LR-M(可能或明确恶性但非肝细胞癌特异)的比例为72.7%(24/33,仅限有慢性肝病风险的33例)。
  • LR-TIV(静脉瘤栓)细分为5V或MV;归为LR-4/5/5V的肉瘤样癌中位直径1.9 cm(范围1.0-4.2 cm),归为LR-M/MV者中位直径4.3 cm(范围1.3-20.6 cm),独立t检验p=0.012。

临床应用与阅片要点

  • 对慢性肝病患者,MRI按LI-RADS v2017评估时多数肉瘤样癌归为LR-M,需与肝内胆管癌鉴别。
  • 小病灶(本研究中LR-4/5/5V组中位1.9 cm)可能被归为LR-4/5/5V而与肝细胞癌难以区分。
  • 靶样表现和包膜回缩在肝内胆管癌中更常见(p≤0.009),有助于与肉瘤样癌鉴别。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate how sarcomatoid carcinomas (SCs) would be classified on magnetic resonance imaging (MRI) by using the Liver Imaging Reporting and Data System (LI-RADS) and to assess imaging features of SC compared with other hepatic malignancies.

METHODS: We retrieved 184 patients with pathologically confirmed SC (n = 46), hepatocellular carcinoma (HCC, n = 92), and intrahepatic cholangiocarcinoma (iCCA, n = 46) diagnosed between January 2006 and December 2017. Two readers independently reviewed MRI according to LI-RADS v2017. Classification rate of SC, as probably or definitely malignant but not specific for HCC (LR-M), was calculated. LR-TIV (tumor in vein) was subclassified as either 5V or MV. MRI features were compared between SC, HCC, and iCCA and between SC of LR-M and non-LR-M categories.

RESULTS: Chronic liver disease was present in 71.7% (33/46) of patients with SC, and LI-RADS was applied for these patients. SC was classified as LR-M in 24 (72.7%) of 33 patients at risk. SCs that had been classified as LR-4/5/5V were significantly smaller (median, 1.9 cm; range, 1.0-4.2 cm) than SCs classified as LR-M/MV (median, 4.3 cm; range, 1.3-20.6 cm) on independent t test (p = 0.012). SCs commonly showed MRI features similar to iCCAs than to HCCs. Targetoid appearance and capsular retraction were more frequent in iCCA than in SC (p ≤ 0.009) on Pearson's chi-squared test or Fisher's exact test.

CONCLUSION: Most SCs can be classified as LR-M on MRI, but small lesions may be indistinguishable from HCCs.

KEY POINTS: • Most sarcomatoid carcinomas (SCs) are classified as LR-M on MRI by using LI-RADS v2017. • SC showed various LR-M features similar to those of intrahepatic cholangiocarcinoma. • Size of LR-4/5/5V SC was significantly smaller than that of LR-M/MV SC.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Seo N, Kim MJ, Rhee H, et al. Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system. Eur Radiol. 2019. PMID: 30859282. doi:10.1007/s00330-019-06052-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。